Advice
Following a full submission.
Oxaliplatin (Eloxatin) is accepted for use within NHS Scotland, in combination with fluorouracil and folinic acid, for the adjuvant treatment of stage III (Dukes’ C) colon cancer after complete resection of the primary tumour.
Addition of oxaliplatin to a standard regimen of fluorouracil and folinic acid increased diseasefree survival in patients who had undergone complete resection of stage III (Dukes’ C) colon cancer. An economic evaluation demonstrated that this is a cost-effective treatment option for these patients.
Treatment with oxaliplatin (Eloxatin) should be under the supervision of an oncologist.
Download detailed advice49KB (PDF)
Medicine details
- Medicine name:
- Oxaliplatin 50mg, 100mg powder for intravenous infusion (Eloxatin®)
- SMC ID:
- 211/05
- Indication:
- Adjuvant treatment of stage III (Dukes' C) colon cancer
- Pharmaceutical company
- Sanofi-Aventis
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 November 2005